BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Mesoblast

Stem Cell Companies | Companies Developing Stem Cell Therapeutics

January 13, 2022 By Cade Hildreth (CEO) 2 Comments

Stem cell companies

Stem cell companies have been rapidly populating on a global basis, reaching nearly 100 market competitors that are developing stem cell therapeutics for use in humans. Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types.

Stem cell research has been going on for over 50 years, because stem cells have a unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to become a wide variety of tissue types, which gives them enormous potential for use in regenerative medicine.

In this article:

  • Leading Stem Cell Companies
    • Mesoblast Ltd.
    • Athersys
    • Pluristem Therapeutics
  • List of Stem Cell Companies

[Read more…]

Filed Under: Stem Cells Tagged With: Athersys, Mesoblast, Pluristem Therapeutics

Mesoblast’s Mesenchymal Precursor Cell (MPC) Therapy Receives Orphan Drug Designation

June 24, 2019 By Cade Hildreth (CEO) Leave a Comment

Mesoblast Revascor

Mesoblast | Type 2 Diabetes Treatment | Companies Developing Cell Therapy Treatments For DiabetesMesoblast (ASX:MSB; Nasdaq: MESO) announced that the U.S. FDA granted the company’s product candidate, Revascor, Orphan Drug Designation for prevention of gastrointestinal bleeding in patients with left ventricular assist devices.

Revascor, Mesenchymal Precursor Cells

Revascor is Mesoblast’s investigational cell therapy composed of 150 million allogeneic mesenchymal precursor cells (MPCs). [Read more…]

Filed Under: MSCs, Stem Cell News Tagged With: Mesoblast, RMAT

Cell Therapy in Asia Erupts with Partnerships and Joint Ventures

January 5, 2017 By Cade Hildreth (CEO) 1 Comment

Cell Therapy in Asia

Cell therapy in Asia has been gathering momentum over the past several years. Japan accelerated its position as a hub for regenerative medicine research, largely driven by support from Prime Minister Shinzo Abe, who identified regenerative medicine and cellular therapy as key to the Japan’s strategy to drive economic growth.

China, South Korea, and other Asian nations have also taken measures to support cell therapy development within their borders. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: Asia, Athersys, cell therapy, Mesoblast, MSC, Pluristem

MD Anderson and NIH to Fund Clinical Trial Combining 2 Mesoblast Technologies

December 9, 2016 By Cade Hildreth (CEO) 1 Comment

Mesoblast, NIH, MD Anderson

On December 6th, MD Anderson Cancer Center and NIH announced that they will be funding a clinical trial that will combine two Mesoblast technologies:

  1. Mesenchymal Precursor Cell (MPC)-based expansion
  2. Ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients

The purpose of the trial is to provide clinical data to indicate whether these technologies can interact synergistically to promote faster cord blood HSC engraftment for bone marrow transplant patients. [Read more…]

Filed Under: MSCs, Stem Cell News Tagged With: cord blood, MD Anderson, Mesoblast, MSC, NIH

Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies

December 8, 2016 By Cade Hildreth (CEO) Leave a Comment

Mesoblast Clinical Trial with MD Anderson

MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients


New York, USA; and Melbourne, Australia; December 6, 2016
: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplMesoblastantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.

The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]

Filed Under: Cord Blood, Exosomes, HSCs, MSCs Tagged With: cord blood, MD Anderson, Mesoblast, MSC

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.